Background Atrial fibrillation (AF) is recognised as a growing clinical and public health problem in many countries, owing to disability and death from stroke associated with the condition, high hospitalisation costs and an increasing prevalence with ageing populations. Undertreatment with oral anticoagulants has been a significant challenge of treatment, historically related to patient concerns over the safety and convenience of warfarin, which until recently was the only oral anticoagulant available. Objectives The aim of this study is to examine: (1) patient preferences for attributes of warfarin and the new oral anticoagulants (dabigatran, rivaroxaban, apixaban) in AF; (2) which attributes are most important; and (3) whether current under-treatment is likely to improve with the new oral anticoagulants. Methods This study was conducted in Melbourne, Australia, with members of the general public with or without AF aged C40 years, where those without AF proxy for newly-diagnosed patients. Participants completed a computerised best-best discrete choice experiment (and followup interview) as if they had AF with a moderate-to-high risk of stroke. Choice data were modelled using mixed rank-ordered logit. Relative value was explored via estimation of marginal rates of substitution with predicted probability analysis used to simulate potential uptake of oral anticoagulants.
Background
Chronic atrial fibrillation (AF), the most common cardiac arrhythmia, is a growing clinical and public health problem in many developed countries. This ''emerging epidemic'' stems from three increasingly recognised realities of AF [1] [2] [3] [4] . First, the health cost is considerable owing to the elevated risk of (preventable) stroke associated with the condition, with high morbidity and mortality. Second, the related hospitalisation costs are considerable given the costs of treating acute stroke and on-going care. Third, these costs are expected to grow exponentially in countries with ageing populations given the prevalence of AF increases with age [1] [2] [3] [4] .
The management of chronic AF is focused on preventing ischaemic stroke and other events that are caused by blood clots 1 preventing normal blood flow to the brain or other areas of the body [5] . Oral anticoagulants are medications that reduce blood clot formation and lower the risk of ischaemic events from occurring. However, by reducing blood clot formation, oral anticoagulants also impede the blood's ability to stop bleeding, which may lead to serious bleeding events including haemorrhagic stroke [6] . Hence, the key clinical trade-off with treatment is achieving a sufficient reduction in ischaemic stroke risk with an acceptable elevation in bleeding risk including (but not limited to) haemorrhagic stroke [7] . Although the risk of disability and death is greater from stroke compared with bleeding events (excluding haemorrhagic stroke), high under-treatment 2 with oral anticoagulants is an ongoing challenge in AF [8] [9] [10] . Historically, this is attributed to patient-related concerns with warfarin (dietary restrictions, frequent blood tests, drug interactions and bleeding adverse events), which was the only oral anticoagulant recommended for AF [11] .
Several new oral anticoagulants (NOACs), including dabigatran, rivaroxaban and apixaban, have recently become available to patients [12] [13] [14] . Although efficacy and safety profiles of the NOACs and warfarin do not vary greatly in absolute terms, key trade-offs exist between the risks and benefits of each. Advantages of the NOACs over warfarin include convenience, with fewer drug or food interactions and no need for International Normalised Ratio (INR) blood tests. Drawbacks include (i) the lack of an emergency ''antidote'' (or reversing agent) used to stop severe bleeding adverse events by restoring normal blood clotting (such as vitamin K for warfarin), and (ii) high patient cost [15, 16] .
Given the expanded range of oral anticoagulants, current under-treatment with warfarin and growing health concerns of AF, it is important to (i) understand how patients value and trade-off the key characteristics of oral anticoagulants and (ii) predict if under-treatment will improve under a number of clinically and policy relevant scenarios. Such information is clinically important to improve shared decision making, and from a policy perspective to forecast medication use [17] . The latter is particularly important given the high prevalence of AF. If uptake is expected to be high this can have important budget implications in countries currently or considering public subsidisation of such medications.
Previous studies have investigated preferences specific to warfarin and/or aspirin [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , thus a key gap in the literature is information on preferences incorporating attributes associated with the NOACs [34] . The existing literature, which used an attributed-based trade-off method (the probability trade-off method) [30] [31] [32] [33] , most of which is over 10 years old, investigated choice between two alternatives varying one attribute at a time (usually stroke risk or bleed risk). By holding other potentially important attributes constant, the relative importance of the attribute included in a trade-off may be biased [35] . This suggests a study using a method that allows investigation of multiple trade-offs simultaneously during the decisionmaking process and includes both warfarin and the NOACs is timely and relevant. To address these issues this study used a discrete choice experiment (DCE).
This study contained a number of novel aspects. While standard practice of DCEs is to ask a single choice per choice-set, asking more choices has been shown to increase efficiency [36] . To maximise the preference information obtained from each participant we used what we refer to as a ''best-best DCE'' where participants were asked to choose their most preferred option per choice-set (or firstbest) and their second-most preferred (or second-best). To help ensure participant understanding and engagement in the study, the computerised survey was narrated by a computer-generated avatar. The best-best DCE was also combined with face-to-face interviews to add further depth of understanding of participant preferences. The aim of this study is to examine: (1) patient preferences for attributes of warfarin and the new oral anticoagulants (dabigatran, rivaroxaban, apixaban) in AF; (2) which attributes are most important; and (3) whether current under-treatment is likely to improve with the new oral anticoagulants.
Methods

Best-Best DCE
DCEs are widely used in health economics to study preferences and the choice of key decision makers [37] [38] [39] [40] , typically implemented as surveys where participants choose between hypothetical and real alternatives presented in a number of choice-sets. This approach assumes that any alternative can be described by a set of attributes that vary over a range of levels. An experimental design is used to combine the attributes and levels to create hypothetical alternatives and the optimal placement of such alternatives into choice-sets to ensure estimation of utility functions of interest and adequate statistical power of the analysis [41] . The choices made between alternatives presented in the choice-sets are modelled within a random utility theory framework to reveal preferences for different alternatives, the relative importance of the attributes and the quantification of the trade-offs made when making such choices [42] . In a standard DCE, participants are typically asked to choose their most preferred alternative in each choice-set. In addition, we asked participants to then choose their preferred alternative from the remaining alternatives in what we have called a best-best DCE. Like a best-worst DCE [36, 43] , this facilitated the elicitation of additional choice observations per choice-set. In contrast to a best-worst DCE where participants switch between selecting the best option then the worst option from those remaining, in a best-best DCE participants choose the best option followed by the best option from those remaining. This also provides full preference ranking for choice-sets with three alternatives.
Study Participants
Study participants were members of the general public aged C40 years and fluent in English. A diagnosis of AF was not an inclusion criterion, thus it was anticipated that both those with and without AF would be represented. The population relevant to the current study are those who are (i) newly-diagnosed (incident population) and (ii) diagnosed with AF (prevalent population); where the groups are differentiated by exposure to previous oral anticoagulant use, which may influence treatment choice [34] . It was not possible to recruit patients who were diagnosed but yet to make a treatment decision. Therefore, those recruited to the study without a diagnosis of AF were considered to proxy for those who are newly-diagnosed. This is considered reasonable given (i) newly-diagnosed patients, like the general public, would not be aware of personal risk profiles before diagnosis, and (ii) the prevalence of AF increases with age (from approximately 40 to 50 years) [44, 45] . This approach is consistent with those used in previous studies [32, 33, [46] [47] [48] , and such participants are also called ''patients at risk'' [34] . Recruitment was via a database of general public research participants maintained at the Centre for Health Economics and via advertising in the Monash University staff newsletter. Consenting participants completed the survey and follow-up interview at Monash University in Melbourne, Australia. The study was approved by the Monash University Human Ethics Committee (MUHREC).
Attributes and Levels
The study included seven attributes (see Table 1 ). Previous studies indicate patient preferences for warfarin are sensitive to the risks of stroke and major bleeding, required INR blood tests, and lifestyle modifications because of drug or food interactions [49] [50] [51] . Important new considerations associated with the NOACs include the high patient cost, lack of antidote and up to twice-daily dosing frequency [15, 16] . This study therefore included key attributes relevant to warfarin and the NOACs.
Attribute descriptions were based on previous trade-off studies [30] [31] [32] [33] , patient decision aids in AF [52, 53] and product information documents for aspirin, warfarin and the NOACs [54] [55] [56] (see Electronic supplementary material 1). Consistent with all previous trade-off studies [30] [31] [32] [33] , a reduction in the risk of (net) stroke is modelled only as a benefit of treatment, rather than both a benefit (decreased risk of ischaemic stroke) and harm (increased risk of haemorrhagic stroke). From the patient perspective, the outcomes of stroke are similar regardless of the type (although haemorrhagic strokes are generally more severe). Therefore, the description of stroke (incorporating both minor and major stroke) used in this study and previous studies [30] [31] [32] [33] is applicable to both ischaemic and haemorrhagic stroke. The concept of net stroke is also consistent with clinical trials of oral anticoagulants that typically combine ischaemic and haemorrhagic stroke as the clinically relevant primary efficacy outcome [12] [13] [14] . Similarly, the description of bleeding used in this study and previous studies [30] [31] [32] [33] does not include haemorrhagic stroke.
The levels describing the risk attributes are based on 'moderate-to-high' stroke risk (4 %) and (major) bleed risk (2 %) without treatment (or untreated AF). These values are associated with a score of 2 on the CHADS 2 3 [57] and HAS-BLED 4 [58] risk indices, which are commonly used to classify untreated patients according to their risk of stroke and bleeding respectively (using individual patient 3 The CHADS 2 risk index estimates stroke risk in AF patients based on the following risk factors: Congestive heart failure, Hypertension, Age C75 years, Diabetes, and prior Stroke, transient ischaemic attach or thromboembolism. 4 The HAS-BLED risk index estimates bleed risk in AF patients based on the following risk factors: Hypertension, Abnormal renal or liver function, prior Stroke, prior Bleeding, Labile INRs, Age C65 years (''Elderly''), current use of Drugs with elevated bleed risk (including alcohol). risk factors). Oral anticoagulants (not aspirin) are recommended in patients with untreated moderate-to-high stroke risk [59] , who represent approximately 30 % of all AF patients [60] . Meta-analyses and randomised controlled trials assessing the efficacy and safety of aspirin, warfarin and the NOACs were identified in a systematic search of the literature [12] [13] [14] 61] . The range of absolute risk levels (vs. 'no treatment') used in the survey was informed by the conduct of indirect comparisons according to the Bucher method using warfarin as the common reference [62] (see Electronic supplementary material 2). The levels of the non-risk attributes were based on a comparison of documented drug profiles and patient costs for aspirin, warfarin and the NOACs in Australia [12-14, 54-56, 61] . This ensured that characteristics of both warfarin and the NOACs were accounted for in the study and the predicted use of specific medication alternatives could be simulated.
Experimental Design
Ngene software (v1.1.1) was used to generate a fractional factorial design that reduced the statistically required number of profiles down to 32, blocked into two versions of 16 choicesets. Participants were randomly assigned to answer one block of 16 choice-sets. Use of a blocked design allowed the number of choice-sets presented to any one participant to be reduced to a number considered manageable in convenience testing (so as not to overburden participants), while harnessing the statistical properties of the full design including all 32 choice-sets [37, 41] . The resulting design was orthogonal and allowed for the estimation of all main effects and an interaction between the bleed risk and antidote. The D-efficacy criterion of the design was 91.19 %, indicating good overall efficiency and statistical power of the design. None of the choice-sets contained ''dominated'' alternatives, meaning no medication alternatives were described by levels that were better or the same as those in the second medication alternative. An additional choice-set with a dominated medication was included as a relatively simple practice question.
Study Format
The best-best DCE was developed as a computerised survey and designed to simulate a typical medical consultation because actual patient decision-making would occur during a consultation. A novel aspect of this study compared with existing AF preference literature, and DCEs in healthcare more generally, was the use of a computer-generated avatar narrating the written text and illustrative images throughout the survey. The survey involved four parts and participants could re-play all information. (1) Participants answered medical and socio-demographic questions in what we referred to as a 'waiting room' questionnaire. (2) Participants were asked to imagine they had been referred to a cardiologist because of an irregular heartbeat and received a diagnosis of AF. (3) Participants were presented with information on AF and oral anticoagulants (including attributes and levels). The concept of risk was explained numerically and diagrammatically using 100 faces, drawing on existing tools to communicate risk to patients [63] . (4) Participants were asked to choose their most and second-most preferred alternatives in the 16 best-best DCE choice-sets (see Electronic supplementary material 3). Each choice-set contained three alternatives: two unlabelled hypothetical medications and 'no treatment' (see example in Fig. 1 ). The 'no treatment' (or opt-out) alternative was described by the risks associated with untreated AF, and allowed participants to opt out of a forced medication choice. The opt-out alternative is important because it increases the realism of the survey and is necessary to model changes to the 'no treatment' alternative and to predict uptake. Following the survey in face-to-face qualitative interviews, participants were asked to discuss how decisions were made, rank the attributes by importance and answer a 10-question quiz to test comprehension of the survey (see Electronic supplementary material 4). The survey was piloted using a small convenience sample (n = 6; male = 3) to test wording, comprehension and timing.
Analysis
Details of the analysis, underlying theory and relevant equations are provided in a technical appendix (see Electronic supplementary material 5). As with standard DCEs, a conditional logit [64] was harnessed to estimate choice models based on first-best data. As both the first-and secondbest alternatives were elicited in each choice-set, data provided a complete ranking over all alternatives in all choicesets. As such, a rank-ordered logit was also estimated.
A rank-ordered (or exploded) logit extends the conditional logit by accounting for the ranked choices within each choice situation [65] . Under the assumptions of the standard logit, the probability of any ranking of the alternatives from best to worst can be expressed as the product of logit formulas. The first logit formula models choice of best from the full choice-set and the second models choice of best from the remaining alternatives after the first-best alternative has been removed (for more detail see Electronic supplementary material 5).
Just as a mixed or random parameter logit model [66] can be estimated on standard DCE first-best data to overcome the well-known limitations of the standard logit model to allow more flexible substitution patterns, preference heterogeneity and permit correlation of the errors over choice situations, it also can be estimated on ranked data by modelling on the product of logits [42] (for more detail see Electronic supplementary Material 5) .
The ranked choice responses were analysed using three, progressive, mixed rank-ordered logit models (in STATA v11), which all included a normally distributed random parameter on the model intercept to allow for unobserved heterogeneity in underlying preferences for treatment compared with 'no treatment'. The choice responses were modelled as the dependent variable and the difference in levels for each of the attributes as the independent variables, with 'no treatment' assumed as the base to ensure identification. Model A included all the attributes as independent variables and a choice-specific constant for 'no treatment'. Model B added an interaction term to examine the relationship between bleed risk and antidote. Model C allowed for observed heterogeneity by including participant characteristics interacted with the intercept and selected treatment attributes to explore the effect of participant characteristics on preferences (see Electronic supplementary material 5 for relevant equations).
The marginal willingness to pay (mWTP) for improvements in each attribute was estimated using the model results via estimation of the marginal rate of substitution for each non-cost attribute with the cost attribute as a reference. Simulation of mWTP is one approach used to quantify the trade-offs that participants were willing to make across attributes and provide a monetary value for a change in each attribute [37] .
Predicted market use of real alternatives was also estimated using model parameters, relevant attribute levels and the mixed rank-ordered logit probability equation. Whilst physician preferences are also important in predicting outcomes of shared decision-making, patient choices can approximate market use under the assumption that patients will not continue taking a medication against their preferences. As no medication labels were used in the survey, real alternatives were simulated using representative attributes and levels derived from the best available data (see Electronic supplementary material 6), and associated probabilities were estimated. The attribute levels of cost and antidote were systematically varied to forecast expected use under different market-place scenarios, given out-of-pocket cost can decrease under government subsidy schemes and NOAC antidotes may be developed in the future [67] . Following good practice guidelines [37] , the model intercept was recalibrated using the probability equation and an iterative process (described in detail in Train 2009, page 33) to reflect current treatment in Australia, which improves the forecasts by accounting for other unobserved factors [42] . Results from face-to-face qualitative interviews, including the direct face ranking of attributes and quiz scores were analysed using summary statistics. Responses to descriptive questions were reviewed and categorised with key quotes identified.
Results
Participants
Between June and July 2012, 76 participants were enrolled and completed the survey and interview at Monash University (no students were included in the sample). Participant characteristics are presented in Table 2 . The average age was 53.3 years (range, 40-79 years) and six participants (7.9 %) had a history of AF. The mean CHADS 2 and HAS-BLED scores were 0.5 and 0.9, respectively, translating to a 2.5 % risk of stroke and 1 % risk of bleeding if untreated. Although the hypothetical untreated risks were higher in the best-best DCE, this is unlikely to be important because, like patients, the participants would not be aware of the risks unless told by a physician. The first and second blocks of 16 choice-sets were answered by 37 and 39 participants, respectively. All participants completed the survey in full and a total of 2,432 modelled DCE questions were answered (two questions per choice-set). The dominated medication in the practice choice-set was never chosen. The mean score of the follow-up quiz was 9.7 out of 10, indicating participants had good comprehension of the survey information. One participant continually selected 'no treatment' as a first choice but stated a dislike to all medication during the follow-up interview. The average time taken to complete the survey was 31 min (range, 22-84 min). Table 3 presents the results of the three mixed rankordered logit models. Following good practice guidelines [37] , a dummy variable controlling for block effects was included in each model and found not to be significant indicating that the block respondents answered had no effect on model results. In Model A, several attribute coefficients were statistically significantly different from zero and their signs were as expected. Significant predictors of choice included stroke and bleed risks, antidote, drug or food interactions, and cost. Participants were more likely to choose more effective (lower stroke risk) and safer (lower bleed risk) alternatives, or alternatives with an antidote. Alternatives with greater potential for drug or food interactions, or those with higher cost were less preferred. The other attributes associated with convenience Fig. 1 Example of a discrete choice experiment choice-set (INR blood tests, dose frequency) were not significant determinants of choice. The coefficient of the random intercept represents the underlying preference for an oral anticoagulant compared with 'no treatment', all else equal. The mean and standard deviation were significantly different from zero, and the standard deviation was large relative to the mean, indicating that on average participants preferred treatment but there was significant heterogeneity over the sample.
Preferences
The interaction between bleed risk and antidote in Model B was significant but its addition resulted in the coefficient for antidote as a main effect losing significance. This indicates that the importance of an antidote depended on the bleed risk, and had no value on its own. The negative value of the interaction coefficient indicated participants were less likely to choose an alternative with an antidote as bleed risk decreased. Alternatively, and more intuitively, sensitivity to bleed risk was reduced if there was an antidote.
Attribute coefficients did not vary with the inclusion of participant characteristics in Model C, although male participants were significantly less likely to choose an oral anticoagulant than 'no treatment'. Model B was selected to estimate mWTP and forecast predicted use based on goodness-of-fit criteria (AIC and BIC). Excluding participants with a history of AF did not alter the modelled results; however, this may be because of the small number of participants rather than no difference in preferences. The full sample was used for the post-estimation analyses as it was considered to be most representative of the relevant population. Table 4 presents the mWTP for improvements of individual attributes (over 1 month of treatment). Participants were willing to pay approximately AUD$50.00 per month for a reduction in absolute stroke risk by one-percentage point. mWTP for an equivalent reduction in bleed risk appears to be dependent on antidote availability, AUD$35.00 with and AUD$55.00 without, although this difference did not reach statistical significance. Similarly, mWTP to have an antidote available appears to be dependent on the level of bleed risk, in the range of -AUD$16.00 to AUD$75.00 over the risk levels used in the survey (2-5 %). A negative mWTP for antidote is unusual given it was described as a 'good' attribute, and suggests participants would have to be paid to accept it. However, the point estimate was not statistically significantly different from AUD$0 and only occurred at the lowest risk of bleeding for which an antidote would be of least value. Table 5 presents the predicted choice of the simulated alternatives in the market, adjusted to reflect the current proportion of untreated patients with moderate-to-high stroke risk in Australia [68] [69] [70] . The modelled probability that a NOAC (without an antidote) would be chosen by this sample is 25 % at the price of AUD$120 per month (approximate patient cost in Australia at the time the study was conducted). At this price, under-treatment (either untreated or aspirin in lieu of oral anticoagulants) is predicted to decrease from 69 to 52 %.
Marginal Willingness to Pay
Predicted Choice
The model predicts the NOACs are more likely to be chosen as the price decreases and/or antidotes are developed. Assuming no antidotes, reducing the patient cost from AUD$120 to AUD$30 per month (approximate patient cost with Australian government general subsidy) increases the probability the NOACs are chosen from 25 to 54 % and under-treatment reduces to 31 %. With antidotes and priced at AUD$30 per month, this probability increases to 70 % and under-treatment decreases to 21 %. HAS-BLED score, mean (SD) 0.9 (0.13)
TAFE technical and further education; NOAC new oral anticoagulant; CHADS2 congestive heart failure, hypertension, age, diabetes, prior stroke; HAS-BLED hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly ([65 years), drugs/alcohol concomitantly, SD standard deviation * These levels were modelled as the base categories for the dummy coded variables in the estimated mixed rank-ordered logit models (Table 3 ) Table 3 Estimated mixed rankordered logit models # *** Significance at 1 % level; ** significance at 5 % level; * significance at 10 % level # Number of participants = 76; number of observations = 2432
In the estimation, stroke risk and bleed risk were modelled as decreasing continuous absolute risks; (more efficacious and safer medications are associated with lower risks); cost and income are modelled as continuous and increasing variables; other attributes are dummy coded $ A positive (negative) sign for a particular attribute implies that level impacted positively (negatively) on utility and therefore increased (reduced) the probability of choosing an alternative with that level 
Direct Ranking of Attributes
The results of the modelled analyses are consistent with the direct ranking of attributes reported in the face-to-face interviews. Of the 76 participants, 68 (89 %) ranked stroke risk and bleed risk as the two most important attributes in the decision-making process, and 58 (76 %) ranked antidote either third or fourth (behind cost). Most participants ranked the convenience factors (blood test, dosing frequency) as being least important. Explanations provided during the interviews indicated that most participants (93 %) believed convenience is unimportant compared with suffering from a stroke or bleed. Of the nine (12 %) participants who ranked bleed risk as being most important, almost all (eight of nine) disclosed a fear of bleeding and/or blood.
Discussion
Based on the study sample, the results indicate particular characteristics of oral anticoagulants are valued more than others for AF when untreated risk levels of stroke and bleeding are moderate to high. Important characteristics include the risks of stroke and major bleeding, whether there is an antidote, the potential for drug or food interactions and cost. Blood tests and the dose frequency were not significant predictors of choice. The mWTP results suggest efficacy was more important than safety, which were both considerably more important than convenience factors. The results also suggest that bleed risk and antidote are related, as the relative importance of bleed risk decreases when there is an antidote. Similarly, the relative importance of an antidote appears to increase with bleed risk, as would be expected. Participants generally indicated in the interviews that they would consider alternatives with higher bleed risk provided it had an antidote, as it offered them ''peace-of-mind''. The prediction analysis suggests the NOACs would not be preferred to warfarin at a patient cost of AUD$120 with only moderately lower undertreatment rates of AF. However, as patient cost decreases, the use of the NOACs is expected to increase with a further decrease in under-treatment. The prediction analysis also suggests if antidotes for the NOACs are developed, undertreatment rates may decrease further again. Although the findings were generally consistent with a priori expectations, the relative unimportance of routine blood testing was initially unexpected, particularly given earlier qualitative patient surveys [49] [50] [51] . However, this finding was supported by interview responses, with some participants regarding routine blood tests as ''normal'' or ''part of life''. This observed relative lack of importance could be explained by the study sample, the majority of whom did not have a history of AF and may not have experienced routine blood testing. This is consistent with evidence that suggests routine INR blood testing is one of the main reasons patients discontinue warfarin [71] , and highlights one way preferences may change after commencing treatment.
This study used mixed methods to investigate preferences, in particular a best-best DCE and face-to-face interviews. Participants were presented with a realistic scenario representative of a typical medical consultation. The content, language and delivery of the survey drew on earlier studies of patient decision aids in AF, which have been shown to improve patients' knowledge of AF, the need for treatment and the ability to make therapeutic decisions [47, 48, 72, 73] . Written text was narrated throughout the survey by a computer-generated avatar, which is novel in the AF preference literature and DCEs in healthcare more generally, but has been shown to significantly improve learning in other literature [74] . Almost all participants indicated that they believed the avatar was helpful in the survey, while a minority reported being indifferent. Some participants stated that the avatar ''personalised'' the survey and assisted to conceptualise the consultation process. Almost all participants correctly answered all survey-based comprehension questions after the DCE (mean score of 9.7 out of 10) indicating background information, including the descriptions of the attributes and levels, was well understood. Unlabelled choice alternatives were used to reduce potential negative preferences associated with the names of anticoagulants, encountered by others [48] . By including an opt-out or 'no treatment' alternative, participants were not forced to choose a medication, thereby increasing the realism of the study [75] . All participants who selected the opt-out indicated in the interviews that 'no treatment' was the preferred alternative when it was chosen, without the desire to try something not included in the choice-set. The sample size was considered reasonable, particularly given, in addition to the DCE (observations = 2432), all 76 participants were individually interviewed. Lack of power in the models was not an issue, particularly given the use of best-best DCE elicitation format doubled the number of observations obtained compared with asking first-best only and produced lower standard errors when compared with a model that only used first-best data. 5 All participants also indicated in the interviews that the best-best format of the DCE caused no confusion or difficulty. The results of the quantitative DCE are well supported by the responses provided in the qualitative follow-up interviews. Specifically, participants articulated the trade-offs they made when choosing alternatives and provided a clear rationale for these, and the direct ranking of attributes was generally consistent with the ranking implied by the DCE.
A number of limitations need to be noted when interpreting the results. First, the study sample included only a small number of AF patients, with the remaining sample considered to proxy for newly-diagnosed patients (incident patients or ''patients at risk''). Whilst this approach is consistent with previous studies, it may limit the generalisability of the results to actual patients. Second, the prediction results require careful interpretation. The analysis was conducted with simulated alternatives using attributes and levels that are representative of real alternatives. The selection of real treatments in practice is also based on shared decision-making between a patient and a physician. Therefore, this analysis is useful in forecasting anticipated trends rather than exact use. Third, the survey simplified the clinical decision problem by combining ischaemic and haemorrhagic strokes with a single net stroke attribute. Although this is consistent with previous studies, the interpretation of the net stroke attribute requires consideration because an increase in the risk of haemorrhagic stroke may not be valued identically as the reduction in the risk of ischaemic stroke. Fourth, the scenario described in the survey was based on untreated moderate-to-high levels of stroke and bleed risks. Whilst this is an important subpopulation of AF patients, preferences could vary at different levels of untreated risks. Finally, despite drawing on best practice approaches to explain risk [63] , the size of the pictorial representation of the risk attributes in the choice-sets may have resulted in additional attention to these attributes and potential for framing effects should be explored in further research.
While the results are no substitute for physicians assessing individual patient preferences, they provide a useful basis for physicians to prioritise issues they discuss with their patients. This study suggests that improving patient affordability of the NOACs may be important for a meaningful improvement in the treatment rate of AF. Whilst many countries have recently decided to subsidise the NOACs, the results also suggest that allaying safety concerns may have a positive effect on treatment rates. Such information is expected to be useful to policy makers forecasting health expenditure as safer oral anticoagulants and/or antidotes are developed.
Future studies could replicate this study to investigate preferences at lower or higher untreated risk levels, and amongst physicians (acting as agents for their patients) in prescribing oral anticoagulants. This would provide additional information regarding preferences and the outcomes of shared decision-making for oral anticoagulants in atrial fibrillation.
Conflict of Interest All authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.
Contributors PG and EL initiated the research and designed the study with SZ. PG and EL undertook the data collection, follow-up interviews and data analyses. PG and EL drafted the manuscript with input from SZ. PG and EL will act as guarantors for the paper. They accept full responsibility for the conduct of the study and controlled the decision to publish.
Ethical approval Approval was obtained from the Monash University Human Ethics Committee (MUHREC). Project Number: CF12/0783-2012000337. All participants gave informed consent before taking part in the study. Participants in the study are not identifiable. Consent was obtained for the study with the provision that participant responses would remain anonymous.
Funding This study was funded by the Centre for Health Economics, Monash University. No other specific funding was received.
